| Product Description |
Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR , HER4 and HER2 , with IC 50 s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity In Vitro Epertinib inhibits the phosphorylation of EGFR and HER2 in NCI-N87 cells, with IC 50 values of 4.5 and 1.6 nM, respectively. Epertinib shows inhibitory activity against MDA-MB-361 cell, with an IC 50 of 26.5 nM. Epertinib (0-10 μM, 72 h) can selectively inhibit the proliferation of a range of cancer cell lines expressing EGFR and/or HER2. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: NCI-N87 (stomach), BT-474 (breast), SK-BR-3 (breast), MDA-MB-453 (breast), MDA-MB-175VII (breast), HT115 (colon), Calu-3 (lung), fR2 (breast), and MRC-5 (lung) Concentration: 0-10 μM Incubation Time: 72 h Result: Inhibited the growth of NCI-N87, BT-474, SK-BR-3, MDA-MB-453, MDA-MB-175VII, HT115, Calu-3, fR2, and MRC-5, with IC 50 values of 8.3 ± 2.6, 9.9 ± 0.8, 14.0 ± 3.6, 48.6 ± 3.1, 21.6 ± 4.3, 53.3 ± 8.6, 241.5 ± 29.2, 5366.7 ± 65.2, and 4964.6 ± 340.3. In Vivo Epertinib (0-100 mg/kg, Orally, once daily for 28 days) shows antitumor activity . Epertinib (50 mg/kg, Orally, once daily for 30 days) significantly reduces the brain tumor volume . Epertinib (0-50 mg/kg, Orally, once daily for 10-28 days) significantly inhibits the tumor growth in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Nude mice (BALB/cAJcl-nu/nu, implanted intracranially with MDA-MB-361 or BR2 cells) Dosage: 12.5, 25, 50, 100 mg/kg Administration: Orally, once daily for 28 days Result: Showed antitumor activity in the mammary fat pad implantation model using both cell lines and the ED 50 values were comparable (24.1 mg/kg and 26.5 mg/kg for MDA-MB-361 and BR2 (MDA-MB-361-luc-BR2), respectively). Animal Model: Nude mice (BALB/cAJcl-nu/nu, implanted intracranially with MDA-MB-361 or BR2 cells) Dosage: 50 mg/kg Administration: Orally, once daily for 30 days Result: Significantly reduced the brain tumor volume, indicating that epertinib could have potent antitumor activity in brain metastasis even in the presence of an intact BTB (blood-tumor barrier). Animal Model: Nude mice (BALB/cAJcl-nu/nu, prepared by subcutaneous implantation of human gastric cancer cells, NCI-N87 into the back of nude mice)Dosage: 0, 6.25, 12.5, 25, and 50 mg/kg Administration: Oral gavage, daily for 10-28 days Result: Significantly inhibited the tumor growth in a dose-dependent manner. Form:Solid IC50& Target:EGFR 1.48 ± 0.0 nM (IC 50 ) HER4 2.49 ± 0.1 nM (IC 50 ) HER2 7.15 ± 0.5 nM (IC 50 ) |
